Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2015-11-04
Last Posted Date
2021-05-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
91
Registration Number
NCT02596971
Locations
🇦🇺

Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States

and more 18 locations

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

First Posted Date
2015-11-01
Last Posted Date
2018-10-16
Lead Sponsor
Seagen Inc.
Target Recruit Count
25
Registration Number
NCT02594163
Locations
🇺🇸

Good Samaritan Hospital, Torrance, California, United States

🇺🇸

Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States

🇵🇱

Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland

and more 47 locations

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting

First Posted Date
2015-07-16
Last Posted Date
2021-05-27
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Target Recruit Count
43
Registration Number
NCT02499627
Locations
🇮🇹

Spedali Civili, Brescia, BS, Italy

🇮🇹

AOU Città della Salute e della Scienza, Torino, TO, Italy

🇮🇹

IRCCS Fondazione Pascale, Napoli, Italy

and more 2 locations

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

First Posted Date
2015-05-15
Last Posted Date
2024-05-09
Lead Sponsor
German CLL Study Group
Target Recruit Count
48
Registration Number
NCT02445131
Locations
🇩🇪

German CLL Study Group, Cologne, Germany

Optimising Renal Outcome in Myeloma Renal Failure

First Posted Date
2015-04-23
Last Posted Date
2022-01-27
Lead Sponsor
Oxford University Hospitals NHS Trust
Target Recruit Count
31
Registration Number
NCT02424851
Locations
🇬🇧

Kent & Canterbury Hospital, Canterbury, United Kingdom

🇬🇧

Royal Liverpool Hospital, Liverpool, United Kingdom

🇬🇧

Heartlands Hospitals, Birmingham, United Kingdom

and more 6 locations

Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

First Posted Date
2015-04-17
Last Posted Date
2018-06-06
Lead Sponsor
University of Chicago
Target Recruit Count
2
Registration Number
NCT02420210
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin

First Posted Date
2015-04-10
Last Posted Date
2021-02-21
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
90
Registration Number
NCT02414568
Locations
🇫🇷

CHR de Metz-Thionville - Hôpital de Mercy, Metz, France

🇫🇷

Hôpital de la Pitié-Salpêtrière, Paris, France

🇫🇷

CHRU de Nîmes, Nîmes, France

and more 37 locations

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2015-03-27
Last Posted Date
2024-06-17
Lead Sponsor
German CLL Study Group
Target Recruit Count
66
Registration Number
NCT02401503
Locations
🇩🇪

German CLL Study Group, Cologne, Germany

© Copyright 2024. All Rights Reserved by MedPath